nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—SLC47A2—Mitoxantrone—breast cancer	0.143	0.27	CbGbCtD
Ondansetron—CYP2D6—breast cancer	0.107	0.538	CbGaD
Ondansetron—CYP3A4—breast cancer	0.0922	0.462	CbGaD
Ondansetron—SLC47A1—Mitoxantrone—breast cancer	0.0595	0.112	CbGbCtD
Ondansetron—CYP1A2—Anastrozole—breast cancer	0.0172	0.0324	CbGbCtD
Ondansetron—CYP1A2—Toremifene—breast cancer	0.0157	0.0296	CbGbCtD
Ondansetron—CYP2C9—Anastrozole—breast cancer	0.0155	0.0292	CbGbCtD
Ondansetron—CYP3A5—Lapatinib—breast cancer	0.0154	0.029	CbGbCtD
Ondansetron—CYP3A4—Exemestane—breast cancer	0.0119	0.0224	CbGbCtD
Ondansetron—CYP2C9—Idarubicin—breast cancer	0.0117	0.0221	CbGbCtD
Ondansetron—CYP2D6—Idarubicin—breast cancer	0.0107	0.0202	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.0103	0.0194	CbGbCtD
Ondansetron—CYP3A7—Tamoxifen—breast cancer	0.0103	0.0194	CbGbCtD
Ondansetron—CYP3A4—Letrozole—breast cancer	0.0101	0.019	CbGbCtD
Ondansetron—CYP2E1—Tamoxifen—breast cancer	0.00994	0.0187	CbGbCtD
Ondansetron—CYP2E1—Mitoxantrone—breast cancer	0.00969	0.0183	CbGbCtD
Ondansetron—CYP3A4—Anastrozole—breast cancer	0.00901	0.017	CbGbCtD
Ondansetron—CYP3A4—Toremifene—breast cancer	0.00824	0.0155	CbGbCtD
Ondansetron—CYP3A7—Paclitaxel—breast cancer	0.00801	0.0151	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.00801	0.0151	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.0079	0.0149	CbGbCtD
Ondansetron—CYP3A7—Irinotecan—breast cancer	0.0079	0.0149	CbGbCtD
Ondansetron—CYP3A5—Tamoxifen—breast cancer	0.00772	0.0145	CbGbCtD
Ondansetron—CYP3A4—Fulvestrant—breast cancer	0.00766	0.0144	CbGbCtD
Ondansetron—CYP3A4—Thiotepa—breast cancer	0.00683	0.0129	CbGbCtD
Ondansetron—CYP2C9—Capecitabine—breast cancer	0.00644	0.0121	CbGbCtD
Ondansetron—CYP3A4—Ixabepilone—breast cancer	0.00625	0.0118	CbGbCtD
Ondansetron—CYP3A4—Lapatinib—breast cancer	0.00601	0.0113	CbGbCtD
Ondansetron—CYP3A5—Paclitaxel—breast cancer	0.00601	0.0113	CbGbCtD
Ondansetron—CYP3A5—Irinotecan—breast cancer	0.00593	0.0112	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00579	0.0109	CbGbCtD
Ondansetron—CYP3A7—Docetaxel—breast cancer	0.00579	0.0109	CbGbCtD
Ondansetron—CYP1A2—Tamoxifen—breast cancer	0.00575	0.0108	CbGbCtD
Ondansetron—CYP2D6—Vinorelbine—breast cancer	0.00525	0.00988	CbGbCtD
Ondansetron—CYP2C9—Tamoxifen—breast cancer	0.00518	0.00975	CbGbCtD
Ondansetron—CYP2D6—Tamoxifen—breast cancer	0.00474	0.00892	CbGbCtD
Ondansetron—CYP3A4—Raloxifene—breast cancer	0.00456	0.00858	CbGbCtD
Ondansetron—CYP3A5—Docetaxel—breast cancer	0.00435	0.00818	CbGbCtD
Ondansetron—CYP1A2—Fluorouracil—breast cancer	0.00424	0.00798	CbGbCtD
Ondansetron—CYP2C9—Paclitaxel—breast cancer	0.00403	0.00759	CbGbCtD
Ondansetron—CYP2C9—Fluorouracil—breast cancer	0.00382	0.00719	CbGbCtD
Ondansetron—CYP3A4—Vinorelbine—breast cancer	0.00334	0.00628	CbGbCtD
Ondansetron—CYP2D6—Vinblastine—breast cancer	0.00323	0.00609	CbGbCtD
Ondansetron—CYP3A4—Tamoxifen—breast cancer	0.00301	0.00567	CbGbCtD
Ondansetron—CYP3A4—Mitoxantrone—breast cancer	0.00294	0.00553	CbGbCtD
Ondansetron—CYP3A4—Paclitaxel—breast cancer	0.00234	0.00441	CbGbCtD
Ondansetron—CYP3A4—Irinotecan—breast cancer	0.00231	0.00435	CbGbCtD
Ondansetron—CYP3A4—Vinblastine—breast cancer	0.00206	0.00387	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—breast cancer	0.00199	0.00374	CbGbCtD
Ondansetron—CYP3A4—Docetaxel—breast cancer	0.00169	0.00319	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—breast cancer	0.00126	0.00238	CbGbCtD
Ondansetron—HTR4—pituitary gland—breast cancer	0.00125	0.108	CbGeAlD
Ondansetron—HTR4—adrenal gland—breast cancer	0.00112	0.0965	CbGeAlD
Ondansetron—Alosetron—CYP3A4—breast cancer	0.000994	1	CrCbGaD
Ondansetron—SLC47A1—nipple—breast cancer	0.000609	0.0524	CbGeAlD
Ondansetron—KCNH2—nipple—breast cancer	0.000373	0.0322	CbGeAlD
Ondansetron—CYP3A7—endocrine gland—breast cancer	0.000371	0.032	CbGeAlD
Ondansetron—SLC47A1—endometrium—breast cancer	0.000367	0.0317	CbGeAlD
Ondansetron—CYP2C9—mammary gland—breast cancer	0.000367	0.0316	CbGeAlD
Ondansetron—SLC47A1—uterus—breast cancer	0.000339	0.0292	CbGeAlD
Ondansetron—SLC47A1—pituitary gland—breast cancer	0.000333	0.0287	CbGeAlD
Ondansetron—SLC47A1—adipose tissue—breast cancer	0.000331	0.0285	CbGeAlD
Ondansetron—CYP1A2—nipple—breast cancer	0.00032	0.0275	CbGeAlD
Ondansetron—SLC47A1—female reproductive system—breast cancer	0.000304	0.0262	CbGeAlD
Ondansetron—SLC47A1—adrenal gland—breast cancer	0.000297	0.0256	CbGeAlD
Ondansetron—SLC47A1—female gonad—breast cancer	0.000277	0.0239	CbGeAlD
Ondansetron—HTR1B—female reproductive system—breast cancer	0.00026	0.0224	CbGeAlD
Ondansetron—SLC47A1—endocrine gland—breast cancer	0.000258	0.0222	CbGeAlD
Ondansetron—OPRM1—endocrine gland—breast cancer	0.00024	0.0207	CbGeAlD
Ondansetron—KCNH2—endometrium—breast cancer	0.000225	0.0194	CbGeAlD
Ondansetron—HTR1B—endocrine gland—breast cancer	0.00022	0.019	CbGeAlD
Ondansetron—KCNH2—uterus—breast cancer	0.000208	0.0179	CbGeAlD
Ondansetron—HTR1A—adrenal gland—breast cancer	0.000205	0.0176	CbGeAlD
Ondansetron—KCNH2—pituitary gland—breast cancer	0.000204	0.0176	CbGeAlD
Ondansetron—KCNH2—female reproductive system—breast cancer	0.000187	0.0161	CbGeAlD
Ondansetron—KCNH2—adrenal gland—breast cancer	0.000182	0.0157	CbGeAlD
Ondansetron—SLC47A1—lymph node—breast cancer	0.000178	0.0153	CbGeAlD
Ondansetron—HTR1A—endocrine gland—breast cancer	0.000178	0.0153	CbGeAlD
Ondansetron—KCNH2—bone marrow—breast cancer	0.000176	0.0152	CbGeAlD
Ondansetron—KCNH2—female gonad—breast cancer	0.00017	0.0146	CbGeAlD
Ondansetron—CYP3A5—adipose tissue—breast cancer	0.000168	0.0145	CbGeAlD
Ondansetron—KCNH2—endocrine gland—breast cancer	0.000158	0.0136	CbGeAlD
Ondansetron—CYP2C9—female reproductive system—breast cancer	0.000152	0.0131	CbGeAlD
Ondansetron—CYP2E1—female reproductive system—breast cancer	0.000144	0.0124	CbGeAlD
Ondansetron—CYP2E1—adrenal gland—breast cancer	0.00014	0.0121	CbGeAlD
Ondansetron—CYP3A5—female gonad—breast cancer	0.00014	0.0121	CbGeAlD
Ondansetron—CYP1A2—endocrine gland—breast cancer	0.000135	0.0117	CbGeAlD
Ondansetron—CYP3A5—endocrine gland—breast cancer	0.000131	0.0112	CbGeAlD
Ondansetron—CYP2C9—endocrine gland—breast cancer	0.000128	0.0111	CbGeAlD
Ondansetron—CYP2E1—endocrine gland—breast cancer	0.000122	0.0105	CbGeAlD
Ondansetron—CYP3A4—female reproductive system—breast cancer	0.000116	0.00997	CbGeAlD
Ondansetron—CYP2D6—female reproductive system—breast cancer	0.000114	0.00981	CbGeAlD
Ondansetron—KCNH2—lymph node—breast cancer	0.000109	0.00941	CbGeAlD
Ondansetron—CYP2D6—female gonad—breast cancer	0.000104	0.00893	CbGeAlD
Ondansetron—CYP3A4—endocrine gland—breast cancer	9.79e-05	0.00844	CbGeAlD
Ondansetron—CYP2D6—endocrine gland—breast cancer	9.64e-05	0.00831	CbGeAlD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	4.96e-05	0.000299	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—breast cancer	4.95e-05	0.000298	CcSEcCtD
Ondansetron—Anaphylactic shock—Docetaxel—breast cancer	4.95e-05	0.000298	CcSEcCtD
Ondansetron—Discomfort—Capecitabine—breast cancer	4.94e-05	0.000297	CcSEcCtD
Ondansetron—Pruritus—Gemcitabine—breast cancer	4.93e-05	0.000297	CcSEcCtD
Ondansetron—Diarrhoea—Irinotecan—breast cancer	4.9e-05	0.000295	CcSEcCtD
Ondansetron—Diarrhoea—Mitoxantrone—breast cancer	4.9e-05	0.000295	CcSEcCtD
Ondansetron—Dry mouth—Capecitabine—breast cancer	4.89e-05	0.000294	CcSEcCtD
Ondansetron—Shock—Docetaxel—breast cancer	4.87e-05	0.000293	CcSEcCtD
Ondansetron—Nervous system disorder—Docetaxel—breast cancer	4.85e-05	0.000292	CcSEcCtD
Ondansetron—Pruritus—Fluorouracil—breast cancer	4.85e-05	0.000292	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—breast cancer	4.84e-05	0.000291	CcSEcCtD
Ondansetron—Visual impairment—Methotrexate—breast cancer	4.84e-05	0.000291	CcSEcCtD
Ondansetron—Tachycardia—Docetaxel—breast cancer	4.83e-05	0.000291	CcSEcCtD
Ondansetron—Feeling abnormal—Paclitaxel—breast cancer	4.81e-05	0.00029	CcSEcCtD
Ondansetron—Skin disorder—Docetaxel—breast cancer	4.81e-05	0.000289	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—breast cancer	4.8e-05	0.000289	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—breast cancer	4.78e-05	0.000288	CcSEcCtD
Ondansetron—Gastrointestinal pain—Paclitaxel—breast cancer	4.78e-05	0.000287	CcSEcCtD
Ondansetron—Diarrhoea—Gemcitabine—breast cancer	4.77e-05	0.000287	CcSEcCtD
Ondansetron—Erythema multiforme—Methotrexate—breast cancer	4.75e-05	0.000286	CcSEcCtD
Ondansetron—Dizziness—Irinotecan—breast cancer	4.74e-05	0.000285	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—breast cancer	4.72e-05	0.000284	CcSEcCtD
Ondansetron—Shock—Capecitabine—breast cancer	4.71e-05	0.000284	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—breast cancer	4.71e-05	0.000283	CcSEcCtD
Ondansetron—Nervous system disorder—Capecitabine—breast cancer	4.7e-05	0.000283	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—breast cancer	4.7e-05	0.000283	CcSEcCtD
Ondansetron—Eye disorder—Methotrexate—breast cancer	4.69e-05	0.000282	CcSEcCtD
Ondansetron—Diarrhoea—Fluorouracil—breast cancer	4.69e-05	0.000282	CcSEcCtD
Ondansetron—Tachycardia—Capecitabine—breast cancer	4.68e-05	0.000281	CcSEcCtD
Ondansetron—Cardiac disorder—Methotrexate—breast cancer	4.66e-05	0.00028	CcSEcCtD
Ondansetron—Skin disorder—Capecitabine—breast cancer	4.65e-05	0.00028	CcSEcCtD
Ondansetron—Urticaria—Paclitaxel—breast cancer	4.64e-05	0.000279	CcSEcCtD
Ondansetron—Hypotension—Docetaxel—breast cancer	4.63e-05	0.000278	CcSEcCtD
Ondansetron—Abdominal pain—Paclitaxel—breast cancer	4.62e-05	0.000278	CcSEcCtD
Ondansetron—Body temperature increased—Paclitaxel—breast cancer	4.62e-05	0.000278	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—breast cancer	4.58e-05	0.000276	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—breast cancer	4.56e-05	0.000274	CcSEcCtD
Ondansetron—Vomiting—Irinotecan—breast cancer	4.55e-05	0.000274	CcSEcCtD
Ondansetron—Vomiting—Mitoxantrone—breast cancer	4.55e-05	0.000274	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—breast cancer	4.54e-05	0.000273	CcSEcCtD
Ondansetron—Dizziness—Fluorouracil—breast cancer	4.54e-05	0.000273	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—breast cancer	4.53e-05	0.000272	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—breast cancer	4.53e-05	0.000272	CcSEcCtD
Ondansetron—Rash—Irinotecan—breast cancer	4.51e-05	0.000272	CcSEcCtD
Ondansetron—Rash—Mitoxantrone—breast cancer	4.51e-05	0.000272	CcSEcCtD
Ondansetron—Dermatitis—Mitoxantrone—breast cancer	4.51e-05	0.000271	CcSEcCtD
Ondansetron—Dermatitis—Irinotecan—breast cancer	4.51e-05	0.000271	CcSEcCtD
Ondansetron—Chills—Methotrexate—breast cancer	4.51e-05	0.000271	CcSEcCtD
Ondansetron—Headache—Mitoxantrone—breast cancer	4.49e-05	0.00027	CcSEcCtD
Ondansetron—Headache—Irinotecan—breast cancer	4.49e-05	0.00027	CcSEcCtD
Ondansetron—Hypotension—Capecitabine—breast cancer	4.48e-05	0.000269	CcSEcCtD
Ondansetron—Paraesthesia—Docetaxel—breast cancer	4.44e-05	0.000267	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—breast cancer	4.44e-05	0.000267	CcSEcCtD
Ondansetron—Vomiting—Gemcitabine—breast cancer	4.43e-05	0.000267	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—breast cancer	4.43e-05	0.000266	CcSEcCtD
Ondansetron—Dyspnoea—Docetaxel—breast cancer	4.41e-05	0.000265	CcSEcCtD
Ondansetron—Somnolence—Docetaxel—breast cancer	4.4e-05	0.000265	CcSEcCtD
Ondansetron—Rash—Gemcitabine—breast cancer	4.4e-05	0.000265	CcSEcCtD
Ondansetron—Dermatitis—Gemcitabine—breast cancer	4.39e-05	0.000264	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—breast cancer	4.39e-05	0.000264	CcSEcCtD
Ondansetron—Erythema—Methotrexate—breast cancer	4.37e-05	0.000263	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—breast cancer	4.37e-05	0.000263	CcSEcCtD
Ondansetron—Headache—Gemcitabine—breast cancer	4.37e-05	0.000263	CcSEcCtD
Ondansetron—Flushing—Epirubicin—breast cancer	4.36e-05	0.000262	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—breast cancer	4.36e-05	0.000262	CcSEcCtD
Ondansetron—Vomiting—Fluorouracil—breast cancer	4.36e-05	0.000262	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—breast cancer	4.35e-05	0.000262	CcSEcCtD
Ondansetron—Rash—Fluorouracil—breast cancer	4.32e-05	0.00026	CcSEcCtD
Ondansetron—Dermatitis—Fluorouracil—breast cancer	4.32e-05	0.00026	CcSEcCtD
Ondansetron—Paraesthesia—Capecitabine—breast cancer	4.3e-05	0.000259	CcSEcCtD
Ondansetron—Hypersensitivity—Paclitaxel—breast cancer	4.3e-05	0.000259	CcSEcCtD
Ondansetron—Headache—Fluorouracil—breast cancer	4.3e-05	0.000258	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Docetaxel—breast cancer	4.27e-05	0.000257	CcSEcCtD
Ondansetron—Dyspnoea—Capecitabine—breast cancer	4.27e-05	0.000257	CcSEcCtD
Ondansetron—Fatigue—Docetaxel—breast cancer	4.27e-05	0.000257	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—breast cancer	4.26e-05	0.000256	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—breast cancer	4.24e-05	0.000255	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—breast cancer	4.24e-05	0.000255	CcSEcCtD
Ondansetron—Constipation—Docetaxel—breast cancer	4.23e-05	0.000255	CcSEcCtD
Ondansetron—Pain—Docetaxel—breast cancer	4.23e-05	0.000255	CcSEcCtD
Ondansetron—Chills—Epirubicin—breast cancer	4.22e-05	0.000254	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—breast cancer	4.2e-05	0.000253	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—breast cancer	4.19e-05	0.000252	CcSEcCtD
Ondansetron—Asthenia—Paclitaxel—breast cancer	4.19e-05	0.000252	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Capecitabine—breast cancer	4.14e-05	0.000249	CcSEcCtD
Ondansetron—Fatigue—Capecitabine—breast cancer	4.13e-05	0.000249	CcSEcCtD
Ondansetron—Pruritus—Paclitaxel—breast cancer	4.13e-05	0.000249	CcSEcCtD
Ondansetron—Vision blurred—Methotrexate—breast cancer	4.12e-05	0.000248	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—breast cancer	4.11e-05	0.000247	CcSEcCtD
Ondansetron—Constipation—Capecitabine—breast cancer	4.1e-05	0.000247	CcSEcCtD
Ondansetron—Pain—Capecitabine—breast cancer	4.1e-05	0.000247	CcSEcCtD
Ondansetron—Erythema—Epirubicin—breast cancer	4.09e-05	0.000246	CcSEcCtD
Ondansetron—Feeling abnormal—Docetaxel—breast cancer	4.08e-05	0.000245	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—breast cancer	4.06e-05	0.000244	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—breast cancer	4.06e-05	0.000244	CcSEcCtD
Ondansetron—Gastrointestinal pain—Docetaxel—breast cancer	4.05e-05	0.000244	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—breast cancer	4.04e-05	0.000243	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—breast cancer	4.04e-05	0.000243	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—breast cancer	4.03e-05	0.000243	CcSEcCtD
Ondansetron—Diarrhoea—Paclitaxel—breast cancer	4e-05	0.00024	CcSEcCtD
Ondansetron—Feeling abnormal—Capecitabine—breast cancer	3.95e-05	0.000238	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—breast cancer	3.94e-05	0.000237	CcSEcCtD
Ondansetron—Malaise—Methotrexate—breast cancer	3.94e-05	0.000237	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—breast cancer	3.93e-05	0.000236	CcSEcCtD
Ondansetron—Gastrointestinal pain—Capecitabine—breast cancer	3.92e-05	0.000236	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—breast cancer	3.92e-05	0.000236	CcSEcCtD
Ondansetron—Body temperature increased—Docetaxel—breast cancer	3.91e-05	0.000235	CcSEcCtD
Ondansetron—Abdominal pain—Docetaxel—breast cancer	3.91e-05	0.000235	CcSEcCtD
Ondansetron—Chills—Doxorubicin—breast cancer	3.9e-05	0.000235	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—breast cancer	3.88e-05	0.000234	CcSEcCtD
Ondansetron—Dizziness—Paclitaxel—breast cancer	3.86e-05	0.000232	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—breast cancer	3.86e-05	0.000232	CcSEcCtD
Ondansetron—Cough—Methotrexate—breast cancer	3.81e-05	0.000229	CcSEcCtD
Ondansetron—Urticaria—Capecitabine—breast cancer	3.81e-05	0.000229	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—breast cancer	3.8e-05	0.000228	CcSEcCtD
Ondansetron—Abdominal pain—Capecitabine—breast cancer	3.79e-05	0.000228	CcSEcCtD
Ondansetron—Body temperature increased—Capecitabine—breast cancer	3.79e-05	0.000228	CcSEcCtD
Ondansetron—Convulsion—Methotrexate—breast cancer	3.79e-05	0.000228	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—breast cancer	3.79e-05	0.000228	CcSEcCtD
Ondansetron—Agitation—Epirubicin—breast cancer	3.76e-05	0.000226	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—breast cancer	3.73e-05	0.000224	CcSEcCtD
Ondansetron—Chest pain—Methotrexate—breast cancer	3.72e-05	0.000224	CcSEcCtD
Ondansetron—Vomiting—Paclitaxel—breast cancer	3.71e-05	0.000223	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.7e-05	0.000222	CcSEcCtD
Ondansetron—Malaise—Epirubicin—breast cancer	3.69e-05	0.000222	CcSEcCtD
Ondansetron—Rash—Paclitaxel—breast cancer	3.68e-05	0.000222	CcSEcCtD
Ondansetron—Dermatitis—Paclitaxel—breast cancer	3.68e-05	0.000221	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—breast cancer	3.68e-05	0.000221	CcSEcCtD
Ondansetron—Syncope—Epirubicin—breast cancer	3.67e-05	0.000221	CcSEcCtD
Ondansetron—Headache—Paclitaxel—breast cancer	3.66e-05	0.00022	CcSEcCtD
Ondansetron—Hypersensitivity—Docetaxel—breast cancer	3.65e-05	0.000219	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—breast cancer	3.62e-05	0.000217	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—breast cancer	3.6e-05	0.000216	CcSEcCtD
Ondansetron—Cough—Epirubicin—breast cancer	3.57e-05	0.000215	CcSEcCtD
Ondansetron—Anaphylactic shock—Methotrexate—breast cancer	3.57e-05	0.000215	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—breast cancer	3.57e-05	0.000215	CcSEcCtD
Ondansetron—Asthenia—Docetaxel—breast cancer	3.55e-05	0.000214	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—breast cancer	3.54e-05	0.000213	CcSEcCtD
Ondansetron—Hypersensitivity—Capecitabine—breast cancer	3.53e-05	0.000212	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—breast cancer	3.51e-05	0.000211	CcSEcCtD
Ondansetron—Pruritus—Docetaxel—breast cancer	3.5e-05	0.000211	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—breast cancer	3.5e-05	0.00021	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—breast cancer	3.48e-05	0.00021	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—breast cancer	3.48e-05	0.000209	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—breast cancer	3.47e-05	0.000209	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—breast cancer	3.47e-05	0.000208	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.46e-05	0.000208	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—breast cancer	3.44e-05	0.000207	CcSEcCtD
Ondansetron—Asthenia—Capecitabine—breast cancer	3.44e-05	0.000207	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—breast cancer	3.41e-05	0.000205	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—breast cancer	3.41e-05	0.000205	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—breast cancer	3.39e-05	0.000204	CcSEcCtD
Ondansetron—Pruritus—Capecitabine—breast cancer	3.39e-05	0.000204	CcSEcCtD
Ondansetron—Diarrhoea—Docetaxel—breast cancer	3.39e-05	0.000204	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—breast cancer	3.34e-05	0.000201	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—breast cancer	3.34e-05	0.000201	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—breast cancer	3.33e-05	0.000201	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—breast cancer	3.33e-05	0.0002	CcSEcCtD
Ondansetron—Cough—Doxorubicin—breast cancer	3.3e-05	0.000199	CcSEcCtD
Ondansetron—Shock—Epirubicin—breast cancer	3.28e-05	0.000198	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—breast cancer	3.28e-05	0.000197	CcSEcCtD
Ondansetron—Diarrhoea—Capecitabine—breast cancer	3.28e-05	0.000197	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—breast cancer	3.27e-05	0.000197	CcSEcCtD
Ondansetron—Dizziness—Docetaxel—breast cancer	3.27e-05	0.000197	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—breast cancer	3.26e-05	0.000196	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—breast cancer	3.24e-05	0.000195	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—breast cancer	3.22e-05	0.000194	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—breast cancer	3.21e-05	0.000193	CcSEcCtD
Ondansetron—Paraesthesia—Methotrexate—breast cancer	3.2e-05	0.000193	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.2e-05	0.000193	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—breast cancer	3.18e-05	0.000192	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—breast cancer	3.18e-05	0.000191	CcSEcCtD
Ondansetron—Somnolence—Methotrexate—breast cancer	3.17e-05	0.000191	CcSEcCtD
Ondansetron—Dizziness—Capecitabine—breast cancer	3.17e-05	0.000191	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—breast cancer	3.15e-05	0.00019	CcSEcCtD
Ondansetron—Vomiting—Docetaxel—breast cancer	3.15e-05	0.000189	CcSEcCtD
Ondansetron—Rash—Docetaxel—breast cancer	3.12e-05	0.000188	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—breast cancer	3.12e-05	0.000188	CcSEcCtD
Ondansetron—Dermatitis—Docetaxel—breast cancer	3.12e-05	0.000188	CcSEcCtD
Ondansetron—Headache—Docetaxel—breast cancer	3.1e-05	0.000187	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—breast cancer	3.09e-05	0.000186	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—breast cancer	3.08e-05	0.000185	CcSEcCtD
Ondansetron—Fatigue—Methotrexate—breast cancer	3.08e-05	0.000185	CcSEcCtD
Ondansetron—Pain—Methotrexate—breast cancer	3.05e-05	0.000184	CcSEcCtD
Ondansetron—Vomiting—Capecitabine—breast cancer	3.05e-05	0.000183	CcSEcCtD
Ondansetron—Shock—Doxorubicin—breast cancer	3.04e-05	0.000183	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—breast cancer	3.03e-05	0.000182	CcSEcCtD
Ondansetron—Rash—Capecitabine—breast cancer	3.02e-05	0.000182	CcSEcCtD
Ondansetron—Dermatitis—Capecitabine—breast cancer	3.02e-05	0.000182	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—breast cancer	3.01e-05	0.000181	CcSEcCtD
Ondansetron—Headache—Capecitabine—breast cancer	3e-05	0.000181	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—breast cancer	3e-05	0.000181	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—breast cancer	3e-05	0.00018	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—breast cancer	2.98e-05	0.000179	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—breast cancer	2.97e-05	0.000179	CcSEcCtD
Ondansetron—Feeling abnormal—Methotrexate—breast cancer	2.94e-05	0.000177	CcSEcCtD
Ondansetron—Gastrointestinal pain—Methotrexate—breast cancer	2.92e-05	0.000176	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—breast cancer	2.89e-05	0.000174	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—breast cancer	2.88e-05	0.000173	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—breast cancer	2.88e-05	0.000173	CcSEcCtD
Ondansetron—Constipation—Epirubicin—breast cancer	2.86e-05	0.000172	CcSEcCtD
Ondansetron—Pain—Epirubicin—breast cancer	2.86e-05	0.000172	CcSEcCtD
Ondansetron—Urticaria—Methotrexate—breast cancer	2.83e-05	0.000171	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—breast cancer	2.82e-05	0.00017	CcSEcCtD
Ondansetron—Body temperature increased—Methotrexate—breast cancer	2.82e-05	0.00017	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—breast cancer	2.77e-05	0.000167	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—breast cancer	2.75e-05	0.000166	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—breast cancer	2.75e-05	0.000166	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—breast cancer	2.75e-05	0.000165	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—breast cancer	2.73e-05	0.000164	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—breast cancer	2.67e-05	0.00016	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—breast cancer	2.66e-05	0.00016	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—breast cancer	2.65e-05	0.00016	CcSEcCtD
Ondansetron—Pain—Doxorubicin—breast cancer	2.64e-05	0.000159	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—breast cancer	2.64e-05	0.000159	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—breast cancer	2.64e-05	0.000159	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—breast cancer	2.64e-05	0.000159	CcSEcCtD
Ondansetron—Hypersensitivity—Methotrexate—breast cancer	2.63e-05	0.000158	CcSEcCtD
Ondansetron—Asthenia—Methotrexate—breast cancer	2.56e-05	0.000154	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—breast cancer	2.55e-05	0.000153	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—breast cancer	2.53e-05	0.000152	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—breast cancer	2.52e-05	0.000152	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—breast cancer	2.46e-05	0.000148	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—breast cancer	2.45e-05	0.000148	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—breast cancer	2.44e-05	0.000147	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—breast cancer	2.44e-05	0.000147	CcSEcCtD
Ondansetron—Diarrhoea—Methotrexate—breast cancer	2.44e-05	0.000147	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—breast cancer	2.4e-05	0.000144	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—breast cancer	2.36e-05	0.000142	CcSEcCtD
Ondansetron—Dizziness—Methotrexate—breast cancer	2.36e-05	0.000142	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—breast cancer	2.28e-05	0.000137	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—breast cancer	2.28e-05	0.000137	CcSEcCtD
Ondansetron—Vomiting—Methotrexate—breast cancer	2.27e-05	0.000136	CcSEcCtD
Ondansetron—Rash—Methotrexate—breast cancer	2.25e-05	0.000135	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—breast cancer	2.25e-05	0.000135	CcSEcCtD
Ondansetron—Headache—Methotrexate—breast cancer	2.23e-05	0.000134	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—breast cancer	2.22e-05	0.000133	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—breast cancer	2.21e-05	0.000133	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—breast cancer	2.19e-05	0.000131	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—breast cancer	2.12e-05	0.000128	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—breast cancer	2.11e-05	0.000127	CcSEcCtD
Ondansetron—Rash—Epirubicin—breast cancer	2.11e-05	0.000127	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—breast cancer	2.1e-05	0.000127	CcSEcCtD
Ondansetron—Headache—Epirubicin—breast cancer	2.09e-05	0.000126	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—breast cancer	2.04e-05	0.000123	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—breast cancer	1.96e-05	0.000118	CcSEcCtD
Ondansetron—Rash—Doxorubicin—breast cancer	1.95e-05	0.000117	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—breast cancer	1.95e-05	0.000117	CcSEcCtD
Ondansetron—Headache—Doxorubicin—breast cancer	1.94e-05	0.000116	CcSEcCtD
Ondansetron—CYP3A4—Metabolism—NCOA3—breast cancer	2.48e-06	2.74e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT2—breast cancer	2.48e-06	2.74e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CB—breast cancer	2.48e-06	2.74e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MDM2—breast cancer	2.48e-06	2.73e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC2A1—breast cancer	2.47e-06	2.73e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NQO1—breast cancer	2.47e-06	2.73e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—breast cancer	2.47e-06	2.73e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RAF1—breast cancer	2.47e-06	2.73e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A2—breast cancer	2.47e-06	2.72e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RELA—breast cancer	2.46e-06	2.71e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—breast cancer	2.45e-06	2.71e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.45e-06	2.71e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—COMT—breast cancer	2.45e-06	2.7e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—breast cancer	2.44e-06	2.7e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB2—breast cancer	2.44e-06	2.7e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—JUN—breast cancer	2.44e-06	2.69e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—breast cancer	2.44e-06	2.69e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—COMT—breast cancer	2.43e-06	2.68e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	2.42e-06	2.68e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CTNNB1—breast cancer	2.42e-06	2.67e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CPT1A—breast cancer	2.42e-06	2.67e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCG2—breast cancer	2.42e-06	2.67e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTR—breast cancer	2.42e-06	2.67e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—breast cancer	2.41e-06	2.67e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP3A4—breast cancer	2.41e-06	2.67e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CB—breast cancer	2.41e-06	2.66e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MTOR—breast cancer	2.41e-06	2.66e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HMOX1—breast cancer	2.4e-06	2.65e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	2.4e-06	2.65e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ITPR1—breast cancer	2.4e-06	2.65e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CD—breast cancer	2.39e-06	2.64e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HMOX1—breast cancer	2.38e-06	2.63e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ITPR1—breast cancer	2.38e-06	2.62e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—breast cancer	2.37e-06	2.62e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1B1—breast cancer	2.37e-06	2.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HPGDS—breast cancer	2.37e-06	2.62e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1A—breast cancer	2.36e-06	2.61e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—breast cancer	2.36e-06	2.61e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SERPINE1—breast cancer	2.36e-06	2.61e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—breast cancer	2.36e-06	2.61e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HBA1—breast cancer	2.35e-06	2.6e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CG—breast cancer	2.34e-06	2.59e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CG—breast cancer	2.34e-06	2.58e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—breast cancer	2.34e-06	2.58e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HSP90AA1—breast cancer	2.33e-06	2.57e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—breast cancer	2.31e-06	2.56e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK8—breast cancer	2.31e-06	2.55e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ABCB1—breast cancer	2.31e-06	2.55e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—breast cancer	2.3e-06	2.54e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—breast cancer	2.3e-06	2.54e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTT1—breast cancer	2.3e-06	2.54e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ACHE—breast cancer	2.3e-06	2.54e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ABCB1—breast cancer	2.29e-06	2.52e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TYMS—breast cancer	2.26e-06	2.5e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NCOA1—breast cancer	2.26e-06	2.5e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1B—breast cancer	2.26e-06	2.5e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOS3—breast cancer	2.25e-06	2.49e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TYMS—breast cancer	2.24e-06	2.48e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—breast cancer	2.24e-06	2.47e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NCOR1—breast cancer	2.24e-06	2.47e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PLA2G4A—breast cancer	2.24e-06	2.47e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—breast cancer	2.24e-06	2.47e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—STK11—breast cancer	2.23e-06	2.46e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP19A1—breast cancer	2.23e-06	2.46e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—breast cancer	2.22e-06	2.45e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PLA2G4A—breast cancer	2.22e-06	2.45e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NCOR1—breast cancer	2.22e-06	2.45e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—breast cancer	2.22e-06	2.45e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—breast cancer	2.21e-06	2.44e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—breast cancer	2.2e-06	2.43e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SRC—breast cancer	2.19e-06	2.42e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP17A1—breast cancer	2.17e-06	2.4e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—breast cancer	2.16e-06	2.38e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS1—breast cancer	2.15e-06	2.38e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ENO1—breast cancer	2.15e-06	2.38e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—JUN—breast cancer	2.15e-06	2.38e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—breast cancer	2.15e-06	2.37e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GPX1—breast cancer	2.14e-06	2.37e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—breast cancer	2.14e-06	2.37e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MDM2—breast cancer	2.14e-06	2.36e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CTNNB1—breast cancer	2.14e-06	2.36e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—breast cancer	2.13e-06	2.35e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RAF1—breast cancer	2.13e-06	2.35e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GPX1—breast cancer	2.12e-06	2.35e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1A1—breast cancer	2.12e-06	2.34e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RELA—breast cancer	2.12e-06	2.34e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP2D6—breast cancer	2.11e-06	2.33e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—breast cancer	2.11e-06	2.33e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB2—breast cancer	2.11e-06	2.33e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ERCC2—breast cancer	2.1e-06	2.32e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1A1—breast cancer	2.1e-06	2.32e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—breast cancer	2.09e-06	2.31e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.09e-06	2.31e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ERCC2—breast cancer	2.09e-06	2.3e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1A—breast cancer	2.09e-06	2.3e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—breast cancer	2.08e-06	2.3e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MTOR—breast cancer	2.08e-06	2.3e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CB—breast cancer	2.08e-06	2.3e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—COMT—breast cancer	2.07e-06	2.29e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NCOA2—breast cancer	2.07e-06	2.29e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—breast cancer	2.06e-06	2.28e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CD—breast cancer	2.06e-06	2.27e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CD—breast cancer	2.05e-06	2.27e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK8—breast cancer	2.04e-06	2.25e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HMOX1—breast cancer	2.03e-06	2.25e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—breast cancer	2.03e-06	2.25e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—breast cancer	2.03e-06	2.24e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ITPR1—breast cancer	2.03e-06	2.24e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—breast cancer	2.03e-06	2.24e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK3—breast cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—FASN—breast cancer	2.01e-06	2.22e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—BCHE—breast cancer	2e-06	2.21e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—breast cancer	2e-06	2.21e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—breast cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MTHFR—breast cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC5A5—breast cancer	1.98e-06	2.18e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MTHFR—breast cancer	1.96e-06	2.17e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—breast cancer	1.96e-06	2.17e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFB1—breast cancer	1.96e-06	2.16e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ABCB1—breast cancer	1.95e-06	2.16e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1B—breast cancer	1.95e-06	2.16e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NOS3—breast cancer	1.94e-06	2.15e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NOS3—breast cancer	1.94e-06	2.14e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SRC—breast cancer	1.93e-06	2.13e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—breast cancer	1.93e-06	2.13e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TYMS—breast cancer	1.92e-06	2.12e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—breast cancer	1.92e-06	2.12e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—breast cancer	1.91e-06	2.11e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—breast cancer	1.91e-06	2.11e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NQO1—breast cancer	1.91e-06	2.11e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A1—breast cancer	1.91e-06	2.11e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—breast cancer	1.9e-06	2.1e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—breast cancer	1.9e-06	2.09e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PLA2G4A—breast cancer	1.9e-06	2.09e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NCOR1—breast cancer	1.9e-06	2.09e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—breast cancer	1.88e-06	2.08e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—breast cancer	1.86e-06	2.06e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—breast cancer	1.86e-06	2.06e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JUN—breast cancer	1.86e-06	2.05e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CTNNB1—breast cancer	1.84e-06	2.04e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1B1—breast cancer	1.83e-06	2.02e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CAV1—breast cancer	1.82e-06	2.02e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GPX1—breast cancer	1.82e-06	2.01e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—breast cancer	1.81e-06	2e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CAV1—breast cancer	1.81e-06	2e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—breast cancer	1.81e-06	2e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1A—breast cancer	1.8e-06	1.99e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1A1—breast cancer	1.8e-06	1.99e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—breast cancer	1.8e-06	1.98e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.79e-06	1.98e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CB—breast cancer	1.79e-06	1.98e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CB—breast cancer	1.79e-06	1.98e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ERCC2—breast cancer	1.78e-06	1.97e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK3—breast cancer	1.78e-06	1.96e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—breast cancer	1.78e-06	1.96e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—breast cancer	1.77e-06	1.96e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK8—breast cancer	1.76e-06	1.94e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—breast cancer	1.75e-06	1.94e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NCOA1—breast cancer	1.75e-06	1.93e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—breast cancer	1.73e-06	1.91e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.73e-06	1.91e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFB1—breast cancer	1.73e-06	1.91e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—STK11—breast cancer	1.72e-06	1.9e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP19A1—breast cancer	1.72e-06	1.9e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—breast cancer	1.69e-06	1.87e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MTHFR—breast cancer	1.68e-06	1.85e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SRC—breast cancer	1.67e-06	1.84e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—breast cancer	1.66e-06	1.84e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CG—breast cancer	1.66e-06	1.84e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CG—breast cancer	1.65e-06	1.82e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—breast cancer	1.62e-06	1.79e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—breast cancer	1.61e-06	1.78e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—breast cancer	1.61e-06	1.78e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—COMT—breast cancer	1.6e-06	1.77e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—breast cancer	1.6e-06	1.77e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—breast cancer	1.59e-06	1.76e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HMOX1—breast cancer	1.57e-06	1.73e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ITPR1—breast cancer	1.57e-06	1.73e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—breast cancer	1.55e-06	1.71e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—breast cancer	1.55e-06	1.71e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CAV1—breast cancer	1.55e-06	1.71e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—breast cancer	1.54e-06	1.7e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK3—breast cancer	1.53e-06	1.7e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—breast cancer	1.51e-06	1.67e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCB1—breast cancer	1.51e-06	1.67e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—breast cancer	1.49e-06	1.65e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFB1—breast cancer	1.49e-06	1.65e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TYMS—breast cancer	1.48e-06	1.64e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.48e-06	1.63e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—breast cancer	1.47e-06	1.63e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—breast cancer	1.47e-06	1.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NCOR1—breast cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—breast cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CD—breast cancer	1.46e-06	1.61e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—breast cancer	1.46e-06	1.61e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CD—breast cancer	1.45e-06	1.6e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—breast cancer	1.44e-06	1.59e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—breast cancer	1.43e-06	1.58e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—breast cancer	1.42e-06	1.57e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CG—breast cancer	1.41e-06	1.56e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GPX1—breast cancer	1.4e-06	1.55e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1A1—breast cancer	1.39e-06	1.53e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NOS3—breast cancer	1.38e-06	1.52e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—breast cancer	1.38e-06	1.52e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ERCC2—breast cancer	1.38e-06	1.52e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NOS3—breast cancer	1.37e-06	1.51e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—breast cancer	1.36e-06	1.5e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—breast cancer	1.36e-06	1.5e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—breast cancer	1.3e-06	1.44e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTHFR—breast cancer	1.29e-06	1.43e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CB—breast cancer	1.27e-06	1.41e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—breast cancer	1.27e-06	1.4e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CB—breast cancer	1.26e-06	1.39e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—breast cancer	1.26e-06	1.39e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—breast cancer	1.25e-06	1.38e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CD—breast cancer	1.24e-06	1.37e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—breast cancer	1.23e-06	1.36e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—breast cancer	1.23e-06	1.35e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—breast cancer	1.22e-06	1.35e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—breast cancer	1.2e-06	1.33e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CAV1—breast cancer	1.19e-06	1.32e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—breast cancer	1.17e-06	1.3e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NOS3—breast cancer	1.17e-06	1.29e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—breast cancer	1.12e-06	1.24e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—breast cancer	1.1e-06	1.22e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—breast cancer	1.09e-06	1.21e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—breast cancer	1.09e-06	1.21e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—breast cancer	1.09e-06	1.21e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CG—breast cancer	1.09e-06	1.2e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CB—breast cancer	1.08e-06	1.19e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—breast cancer	1.07e-06	1.18e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—breast cancer	1.04e-06	1.14e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CD—breast cancer	9.55e-07	1.06e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—breast cancer	9.43e-07	1.04e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—breast cancer	9.32e-07	1.03e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NOS3—breast cancer	9.02e-07	9.96e-06	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—breast cancer	8.94e-07	9.87e-06	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—breast cancer	8.92e-07	9.85e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CB—breast cancer	8.33e-07	9.2e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—breast cancer	8.25e-07	9.11e-06	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—breast cancer	7.76e-07	8.58e-06	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—breast cancer	7.7e-07	8.5e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—breast cancer	7.19e-07	7.95e-06	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—breast cancer	6.58e-07	7.27e-06	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—breast cancer	6.34e-07	7.01e-06	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—breast cancer	6.29e-07	6.95e-06	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—breast cancer	5.37e-07	5.93e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—breast cancer	5.08e-07	5.61e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—breast cancer	4.15e-07	4.58e-06	CbGpPWpGaD
